These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28841855)

  • 21. Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer.
    Tanaka N; Asakawa I; Fujimoto K; Anai S; Hirayama A; Hasegawa M; Konishi N; Hirao Y
    BMC Urol; 2012 Sep; 12():28. PubMed ID: 22974428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matching.
    Nakai Y; Tanaka N; Asakawa I; Ohnishi K; Miyake M; Yamaki K; Torimoto K; Fujimoto K
    Prostate; 2024 Sep; 84(12):1104-1111. PubMed ID: 38734992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.
    Burri RJ; Stone NN; Unger P; Stock RG
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1338-44. PubMed ID: 20138442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
    Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
    Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.
    Fellin G; Mirri MA; Santoro L; Jereczek-Fossa BA; Divan C; Mussari S; Ziglio F; La Face B; Barbera F; Buglione M; Bandera L; Ghedi B; Di Muzio NG; Losa A; Mangili P; Nava L; Chiarlone R; Ciscognetti N; Gastaldi E; Cattani F; Spoto R; Vavassori A; Giglioli FR; Guarneri A; Cerboneschi V; Mignogna M; Paoluzzi M; Ravaglia V; Chiumento C; Clemente S; Fusco V; Santini R; Stefanacci M; Mangiacotti FP; Martini M; Palloni T; Schinaia G; Lazzari G; Silvano G; Magrini S; Ricardi U; Santoni R; Orecchia R
    Br J Radiol; 2016 Sep; 89(1065):20150981. PubMed ID: 27384381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
    Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
    BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapy.
    Tanaka N; Nakai Y; Asakawa I; Yamaki K; Miyake M; Hori S; Owari T; Fujii T; Fujimoto K
    Int J Urol; 2022 Dec; 29(12):1560-1568. PubMed ID: 36125928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Radiat Oncol; 2017 Jun; 12(1):98. PubMed ID: 28615058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
    Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
    BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.
    Pickles T; Keyes M; Morris WJ
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):43-9. PubMed ID: 19570619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
    Makino T; Mizokami A; Namiki M
    Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose rate brachytherapy for men with localized prostate cancer.
    Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
    Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
    Buyyounouski MK; Horwitz EM; Uzzo RG; Price RA; McNeeley SW; Azizi D; Hanlon AL; Milestone BN; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1383-91. PubMed ID: 15275723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy.
    Boehle A; Katic K; König IR; Robrahn-Nitschke I; Brandenburg B
    Brachytherapy; 2020; 19(1):24-32. PubMed ID: 31629640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.
    Lazarev S; Thompson MR; Stone NN; Stock RG
    BJU Int; 2018 May; 121(5):781-790. PubMed ID: 29319928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT.
    Deutsch I; Zelefsky MJ; Zhang Z; Mo Q; Zaider M; Cohen G; Cahlon O; Yamada Y
    Brachytherapy; 2010; 9(4):313-8. PubMed ID: 20685176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer.
    Tsumura H; Tanaka N; Oguchi T; Owari T; Nakai Y; Asakawa I; Iijima K; Kato H; Hashida I; Tabata KI; Satoh T; Ishiyama H
    Radiat Oncol; 2022 Apr; 17(1):71. PubMed ID: 35410307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.